X4 PHARMACEUTICALS XFOR 深 沪
已收盘 12-12 16:00:00 美东时间
3.91
+0.030
+0.77%
华盛通- 最 高4.0784
- 今 开3.87
- 成交量 52.56万股
- 最 低 3.77
- 昨 收 3.88
- 总市值 3.42亿
- 52周最高 26.829
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 1.35
- 委 比 -99.83%
- 总股本 8743.67万
- 历史最高 717.90
- 量 比 0.65
- 振 幅 7.95%
- 历史最低 3.77
- 每 手 1
- 风险率 5.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
12-08 08:34
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10
Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.
12-06 01:29
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
X4 Pharmaceuticals Q3 EPS $(0.69) Beats $(0.82) Estimate, Sales $1.765M Miss $1.901M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.82) by 15.85 percent. This is a 87.41 percent increase over losses of $(5.48) per share
11-05 21:22
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals announced Q3 2025 financial results, focusing on advancing the 4WARD Phase 3 chronic neutropenia trial. The company achieved $240.3M in financings, reducing workforce by 50% to save $13M annually. Cash runway extends to end of 2028, enabling completion of the 4WARD trial and potential launch of mavorixafor in this indication.
11-05 12:00
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
X4 Pharmaceuticals completed a public offering of 52,844,000 shares at $2.90 per share, raising approximately $155.3 million before expenses. The offering included an additional 6,984,000 shares and pre-funded warrants for 700,000 shares. Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunners. The company plans to use the proceeds for its operations, including advancing its pipeline in rare hematology diseases.
10-27 23:05
X4 Pharmaceuticals drops 5%, prices $135M equity
X4 Pharmaceuticals (NASDAQ:XFOR) priced its previously announced underwritten public offering of 45.86M shares at $2.90 and warrants to purchase up to 700K shares at a public offering price of $2.899 ...
10-24 14:52
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
X4 Pharmaceuticals has priced its underwritten public offering of 45.86 million shares at $2.90 per share, with pre-funded warrants for up to 700,000 shares at $2.899. The offering is expected to raise approximately $135 million before expenses and close on October 27. Proceeds will fund pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders and general corporate purposes.
10-24 04:37
X4 Pharmaceuticals to reduce 50% of workforce
X4 Pharmaceuticals (NASDAQ:XFOR) has announced a restructuring program to align resources with its long-term strategy to complete the Phase 3 4WARD trial for chronic neutropenia. The plan includes cut...
09-17 19:33
X4 Pharmaceuticals Announces Major Strategic Restructuring
X4 Pharmaceuticals ( ($XFOR) ) has provided an update. On September 17, 2025, X...
09-17 19:29
